Seeking Alpha

Seeking Alpha Portfolio App for iPad

1,424 people get ONTY articles and Market Currents by email alert.

Get email alerts on ONTY »

ONTY

Oncothyreon Inc .

5/22/2013, 11:23 PM ET

Quote & Headlines Market Currents StockTalk

All
| Earnings
| Dividends
| M&A
| On the move

Friday, May 17, 3:56 PM Oncothyreon (ONTY +0.9%) gets a boost from Wedbush today, as the firm upgrades he stock to Outperform and raises the price target from $2 to $5. Wedbush says that its partner Merck KgA may be successful in negotiating a path to approval for Stimuvax with the existing and anticipated new data from ongoing clinical trials. Merck expects to provide an update on their discussion with regulators in 2013. 1 Comment [Healthcare, On the Move]
Thursday, May 16, 12:55 PM Oncothyreon (ONTY -20.7%) tanks today after presenting data as ASCO that showed Phase III trials of its investigational MUC1 antigen-specific cancer immunotherapy L-BLP25 didn't meet its primary objective. The trial was conducted by Merck Serono, a division of Merck (MRK -0.7%), under a license agreement with ONTY. 3 Comments [Healthcare, On the Move]
Thursday, May 16, 12:51 PM Midday top 10 gainers: EGLE +46%. NBG +24%. SBSA +23%. DQ +22%. GNK +19%. AEGR +19%. GLBS +17%. SINO +17%. PRGN +16%. LWAY +16%.
Midday top 10 losers: NCT -54%. SNFCA -22%. ONTY -21%. INFI -19%. CNIT -15%. CYCC -14%. PTSX -14%. AMD -13%. BDCO -11%. TRIT -11%. 2 Comments [On the Move]
Thursday, May 9, 5:54 PM After-hours top gainers, as of 5:30 p.m.: UBNT +10%. UNIS +10%. MCP +7%. WIFI +7%. DAR +6%.
After-hours top losers: ONTY -10%. AL -8%. AIRM -7%. SNTS -6%. TSEM -6%. Comment! [On the Move]
Friday, March 15, 3:08 PM Oncothyreon (ONTY +0.9%) moves up today on a better than expected Q4 report yesterday, largely shrugging off Cantor Fitzgerald's slashing of its price target to $4.00 from $11.00. The cut relates to ONTY's loss of Stimuvax. Cantor says that despite partner Merck's (MRK) assertion that treatment effects were observed in sub-populations, its financial model assumes that commercialization does not occur and no value is included in its valuation. Comment! [Healthcare, On the Move, Earnings]
Thursday, March 14, 8:17 AM Oncothyreon (ONTY): Q4 EPS of -$0.12 beats by $0.02. (PR) Comment! [Earnings, Breaking News, Healthcare]
Wednesday, January 2, 9:10 AM Premarket gainers: ZIP +47.94%. POL +18.71%. SGYP +16.92%. MCP +9%. JRCC +8.41%. PAL +7.69%. KWK +7.69%. ZGNX +7.52%. PPHM +6.82%. ONTY +6.77%.
Losers: ABT -50%. 6 Comments
Wednesday, December 19, 2012, 12:45 PM Midday top 10 gainers: AMPL +119%. DYNT +64%. EDAP +25%. ALTE +24%. STP +16%. PTNR +13%. LDK +12%. GBR +19%. CSUN +12%. ELTK +12%.
Midday top 10 Losers: ONTY -54%. CMGE -21%. PLXT -18%. NICK -15%. DLB -12%. PNTR -11%. PSDV -10%. EGLE -10%. CCUR -10%. PTEK -10%. Comment! [On the Move]
Wednesday, December 19, 2012, 9:10 AM Premarket gainers: PTNR +11%. GM +9%. KCG +8%. RMCF +6%. NBG +6%. VRNG +6%. MLNX +5%.
Losers: ONTY -61%. PLXT -18%. NAV -6%. CYS -6%. 3 Comments [On the Move]
Wednesday, December 19, 2012, 8:39 AM Stimuvax, a lung cancer vaccine that Germany's Merck (MKGAF.PK) has licensed from Oncothyreon (ONTY), failed to improve overall survival in a Phase III study. However, "notable treatment effects were observed in certain subgroups of patients." That's not enough to convince analysts: "Despite potential positive effects in subgroups, we consider the drug dead," says Deutsche Bank. Oncothyreon collapses 61%, while Merck is -2.9% in Frankfurt. (PR) Comment! [On the Move, Healthcare]
Wednesday, November 7, 2012, 4:53 PM Oncothyreon (ONTY): Q3 EPS of -$0.15 in-line. (PR) Comment! [Earnings, Healthcare]
Wednesday, November 7, 2012, 12:10 AM Notable earnings after Wednesday’s close: ARAY, ATO, ATVI, AWK, BONE, CBS, CLR, CODI, CPE, CPNO, CTL, CXO, ETE, ETP, EXEL, FTK, GMXR, GSS, HIMX, HNSN, ITMN, KGC, MAKO, MBI, MDLZ, MNST, MWE, NQ, OAS, ONTY, OSUR, PAAS, PANL, PRI, PRU, QCOM, SGEN, SLXP, SNTS, SRZ, SSRI, SXL, TCAP, TIE, TS, WFM Comment! [Earnings]
Tuesday, November 6, 2012, 5:35 PM Notable earnings after Wednesday’s close: ARAY, ATO, ATVI, AWK, BONE, CBS, CLR, CODI, CPE, CPNO, CTL, CXO, ETE, ETP, EXEL, FTK, GMXR, GSS, HIMX, HNSN, ITMN, KGC, MAKO, MBI, MDLZ, MNST, MWE, NQ, OAS, ONTY, OSUR, PAAS, PANL, PRI, PRU, QCOM, SGEN, SLXP, SNTS, SRZ, SSRI, SXL, TCAP, TIE, TS, WFM Comment! [Earnings]
Friday, August 24, 2012, 10:38 AM Oncothyreon (ONTY +10.8%) pops after Stifel Nicolaus initiated coverage this morning with a Buy. Not much detail is given, but a couple of catalysts are worth noting. First, its lead product candidate, Stimuvax, is a cancer vaccine in the latter stages of being evaluated in two Phase 3 clinical trials for the treatment of non-small cell lung cancer, with the results due out in early 2013. Second, the shares have lost nearly half their market value since early March, and with the stock currently trading off its 50-day moving average as support, it could be spring-loaded for an upside surprise. Comment! [Healthcare, On the Move]
Friday, August 24, 2012, 9:10 AM Premarket gainers: ARUN +14%. MTSL +12%. CPRX +10%. LLY +8%. DSCO +7%. FRO +5%. ONTY +5%.
Losers: ADSK -22%. HMSY -5%. Comment! [On the Move]
Wednesday, August 8, 2012, 12:10 AM Notable earnings after Wednesday’s close: ATPG, AUY, AVNR, CJES, CLR, CPE, CPNO, CTL, EGLE, EXXI, FTK, GMXR, GSS, GXP, HNSN, HOGS, KGC, MBI, MDRX, MM, MNST, NQ, NWSA, ONTY, PANL, SATC, SCLN, SGEN, SPWR, TEG, ZGNX Comment! [Earnings]